Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
Portfolio Pulse from
Sangamo Therapeutics, Inc. has received IND clearance for a phase 1/2 study of ST-503 for idiopathic small fiber neuropathy and entered a partnership with Astellas for neurological disorder treatments, potentially earning up to $1.3 billion in milestone payments.
December 19, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics received IND clearance for ST-503 and partnered with Astellas, potentially earning $1.3 billion in milestone payments.
The IND clearance for ST-503 and the partnership with Astellas are significant developments for Sangamo. The potential $1.3 billion in milestone payments and the expansion into neurological disorders could positively impact SGMO's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100